ethyl 2-[3-(2,6-dichlorophenylamino)-6-oxo-1,6-dihydropyridazin-1-yl]acetate | 1350848-88-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-[3-(2,6-dichlorophenylamino)-6-oxo-1,6-dihydropyridazin-1-yl]acetate
• 英文别名: Ethyl 2-[3-(2,6-dichlorophenylamino)-6-oxo-1,6-dihydropyridazin-1-yl] acetate；ethyl 2-[3-(2,6-dichloroanilino)-6-oxopyridazin-1-yl]acetate
• CAS: 1350848-88-2
• 化学式: C₁₄H₁₃Cl₂N₃O₃
• 分子量: 342.182
• InChiKey: GBDSNWYUPVYTNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,6-二氯苯胺 在 potassium carbonate 、 溶剂黄146 作用下， 以 异丙醇 、 丙酮 为溶剂， 反应 33.0h， 生成 ethyl 2-[3-(2,6-dichlorophenylamino)-6-oxo-1,6-dihydropyridazin-1-yl]acetate
  参考文献：
  名称：

  Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivatives

  摘要：

  A series of pyridazinone-containing compounds were designed and synthesized as congeners for diclofenac, the most potent and widely used NSAID. The target compounds were evaluated for their anti-inflammatory activity on rat paw edema inflammation model against diclofenac as a reference compound. Seven of the tested compounds demonstrated more than 50% inhibition of carrageenan-induced rat paw edema at a dose 10 mg/kg. The compounds, 6-(2-bromophenylamino)pyridazin-3(2H)-one 2a and 6-(2,6-dimethylphenylamino)pyridazin-3(2H)-one 2e, displayed 74 and 73.5% inflammation-inhibitory activity, respectively, which is comparable to diclofenac (78.3%) at the same dose level after 4 h. The most active compounds as anti-inflammatory agents, 2a, 2e, and 6a, displayed fewer number of ulcers and milder ulcer score than indomethacin in ulcerogenicity screening.

  DOI：

  10.1007/s00044-011-9895-7

文献信息

• Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivatives
  作者：K. A. M. Abouzid、N. A. Khalil、E. M. Ahmed、A. Esmat、A. M. Al-Abd

  DOI：10.1007/s00044-011-9895-7

  日期：2012.11

  A series of pyridazinone-containing compounds were designed and synthesized as congeners for diclofenac, the most potent and widely used NSAID. The target compounds were evaluated for their anti-inflammatory activity on rat paw edema inflammation model against diclofenac as a reference compound. Seven of the tested compounds demonstrated more than 50% inhibition of carrageenan-induced rat paw edema at a dose 10 mg/kg. The compounds, 6-(2-bromophenylamino)pyridazin-3(2H)-one 2a and 6-(2,6-dimethylphenylamino)pyridazin-3(2H)-one 2e, displayed 74 and 73.5% inflammation-inhibitory activity, respectively, which is comparable to diclofenac (78.3%) at the same dose level after 4 h. The most active compounds as anti-inflammatory agents, 2a, 2e, and 6a, displayed fewer number of ulcers and milder ulcer score than indomethacin in ulcerogenicity screening.